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Abstract 
Introduction  
Recent studies showed improved patient outcomes with endovascular treatment of acute 
stroke compared to medical care, including IV rtPA, alone. Seven trials have reported results, 
each using different clinical and imaging criteria for patient selection. We compared 
eligibility for different trial protocols to estimate the number of patients eligible for treatment. 
Patients and Methods: 
Patient data were extracted from a single centre database that combined patients recruited to 
three clinical studies, each obtained both CTA and CTP within 6h of stroke onset. The 
published inclusion and exclusion criteria of seven intervention trials (MR CLEAN, 
EXTEND–IA, ESCAPE, SWIFT-PRIME, REVASCAT, THERAPY and THRACE) were 
applied to determine the proportion that would be eligible for each of these studies. 
Results: 
A total of 263 patients was included.    Eligibility for IAT in individual trials ranged from 
53% to 3% of patients; 17% were eligible for 4 trials and under 10% for 2 trials. Only three 
patients (1%) were eligible for all studies. The most common cause of exclusion was absence 
of large artery occlusion (LAO) on CTA. When applying simplified criteria requiring and 
ASPECT score >6, 16% were eligible for IAT, but potentially 40% of these patients were 
excluded by perfusion criteria and more than half by common NIHSS thresholds.    
Conclusion: 
Around 15% of patients presenting within 6h of stroke onset were potentially eligible for 
IAT, but clinical trial eligibility criteria have much more limited overlap than is commonly 
assumed and only 1% of patients fulfilled criteria for all recent trials.    
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Introduction: 
Between December 2014 and April 2015, five clinical trials were published that showed 
benefit of intra-arterial therapy (IAT), predominantly using stent-retrievers for 
thrombectomy, in a subset of acute stroke patients with large artery occlusion (LAO), 
compared to best medical care (including intravenous recombinant tissue plasminogen 
activator (IV rtPA) in the majority)1-5. Two further trials have presented similar findings6, 7. 
The success of these trials, compared to previous studies of IAT, was attributed to better 
patient selection (including the use of advanced imaging), streamlined study procedures to 
achieve rapid revascularization, and the use of stent retriever devices, capable of producing 
high rates of recanalization 8.  
Introduction of IAT to routine acute stroke care requires re-organization of stroke services so 
that patients most likely to benefit are rapidly directed to centres where endovascular services 
are available. Each of the published or presented IAT trials used different clinical and 
imaging criteria for patient selection (summarized in table 1). While opinion supports the 
concept that a common group of readily identifiable patients has been studied in all IAT 
trials,8, 9 we hypothesised that if so, then a substantial proportion of patients with acute stroke 
would be eligible for multiple trial protocols. We tested this by applying trial entry criteria to 
a database of acute stroke patients, all of whom underwent CT angiography (CTA) and CT 
perfusion (CTP) in addition to non-contrast CT in the acute stage in order to estimate the 
number of patients potentially eligible for IAT, and to compare eligibility across different 
trials.   
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Patients and Methods: 
Patient data were extracted from an acute stroke imaging database that combined patients 
recruited from three acute studies that acquired multimodal CT less than 6 hours after 
symptom onset (the multicentre acute stroke imaging study [MASIS],10 post-stroke 
hyperglycemia [POSH]11 and Alteplase-Tenecteplase Trial Evaluation for Stroke 
Thrombolysis [ATTEST]12 studies) at a single centre between 2008 and 2013. Two studies 
were observational studies evaluating feasibility of complex imaging and the 
pathophysiology of hyperglycemia respectively (MASIS and POSH), while the third 
(ATTEST) compared two different IV thrombolytic agents within 4.5 hours of symptom 
onset. Entry and exclusion criteria are detailed in supplementary material. Endovascular 
treatment was not undertaken. Clinical details included demographic and risk factor data, 
National Institutes of Health Stroke Scale (NIHSS) 13 scores at onset and 24 hours, estimated 
pre-morbid modified Rankin Scale (mRS)14, time from symptom onset to CT and to treatment 
(if applicable). All patients had non-contrast CT (NCCT), CT perfusion (CTP) and CT 
angiography (CTA) at presentation.  This was performed using a multi-detector Scanner 
(Philips Brilliance 64 Slice). Whole brain non-contrast CT was acquired first, followed by CT 
perfusion with 40mm slab coverage (8x5mm slices), using a 50 ml contrast bolus 
administered at 5mls/second via a large-gauge peripheral venous cannula. Finally a CT 
angiogram was performed from aortic arch to the top of the lateral ventricles using bolus 
tracking to enable correct timing of image acquisition.   
CTP was processed offline with MiStar (Apollo Medical Imaging Technology, Melbourne, 
VIC, Australia) to produce Cerebral Blood Flow (CBF) and Cerebral Blood Volume (CBV), 
Delay Time (DT) and Mean Transient Time (MTT) maps.   Ischaemic core was defined as 
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tissue with reduced CBF (relative CBF <40% of contralesional hemisphere) and prolonged 
delay time (relative DT >2 sec); penumbra volume was defined as tissue with relative DT >2 
sec but relative CBF ≥ 40% of contralateral15. To account for the limited z-axis coverage of 
CTP, we reduced the 70ml threshold used by EXTEND-IA16 and DEFUSE-217  
proportionately. Detailed scan acquisition detailed were previously published18 .We also 
evaluated baseline NCCT for ASPECT scores 19. 
The published inclusion and exclusion criteria of 7 intervention trials (MR-CLEAN1, 
EXTEND–IA3, ESCAPE2, SWIFT-PRIME4, 20, REVASCAT5, THERAPY 7and THRACE6 
were applied to determine eligibility for each study. Minor modifications of inclusion criteria 
were required to match our data set, as detailed in Supplementary material.  
Individual trial criteria were applied to each individual case and eligibility for all possible 
combinations of trial eligibility were tabulated. We compared patient characteristics of the 
cases selected from our population with those of each trial. Finally, we calculated the number 
of patients that would be eligible for IAT in a hypothetical clinical setting using simplified 
eligibility criteria more reflective of clinical practice.  
 
Results 
A total of 263 patients were included (60% male, mean age 70.6yrs).  Clinical features in our 
patients were comparable to those of patients recruited in the published trials, with the 
exception of a notably lower median NIHSS score on admission compared to trial 
populations for EXTEND-IA, SWIFT-Prime and REVASCAT, and a longer median onset to 
IV rtPA administration time (table 2 in supplementary material). 
Figure 1 shows the numbers of patients meeting eligibility criteria for each of the seven 
studies. The widest eligibility criteria identified 53% of patients as potentially eligible for 
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IAT (for MR CLEAN), declining to 3% for the most restrictive (THERAPY). Figure 2 shows 
the number of patients eligible for different study combinations, and Figure 3 shows the 
number of patients excluded by applying the most restrictive inclusion criteria sequentially to 
our patients. Only 3 patients fulfilled eligibility criteria for all studies.  One quarter of the 
patients excluded based on the narrowest NIHSS range had LAO (Table 1 in Supplementary 
material). The number of patients excluded based on perfusion or ASPECTS selection varied 
from 24% to 62%, depending on the site of occlusion and the tissue criteria used (figure 2 in 
supplementary material). 
Figure 4 shows the selection process in a hypothetical clinical setting. Using two simple 
imaging criteria for patient selection, presence of LAO and ASPECT score >6, 16% of 
patients would be considered for IAT.  The numbers would be reduced further if selection 
was restricted by onset to treatment time, NIHSS thresholds, or the use of CTP. 
 
Discussion: 
Recently published studies have shown that IAT improves outcome in selected patients with 
large artery occlusive stroke, predominantly as an adjunct to IV rtPA. Since all individual 
trials were small or modest in size, conducted at highly experienced acute stroke centres, and 
with somewhat different eligibility criteria, it is important to establish the comparability of 
populations across different trials, both for data pooling and for service planning. Recent 
group-level meta-analysis identified significant heterogeneity among published trials 21. 
When applied to a population of acute stroke patients presenting within 6h of symptom onset 
and with advanced imaging available, but otherwise minimally selected, we found that the 
number of patients eligible for the different studies individually ranged between 3% and 53% 
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of all patients in our database, and for all trial protocols except MR CLEAN was <20%. Only 
14% would have been eligible for 3 or more of the recent trials. 
The most important clinical selection criterion is the NIHSS score, excluding more than 50% 
of patients when the narrowest range is applied. Previous studies suggested NIHSS score 
thresholds above 7 - 10 to be associated with higher probability of LAO22, 23. Since any given 
NIHSS threshold has limited positive predictive value 24, 25, however, trials will inevitably 
arbitrarily restrict recruitment of angiographically appropriate patients by setting NIHSS 
thresholds. The median NIHSS of patients treated by IAT in published studies was 17, 
regardless of the pre-specified threshold in protocol inclusion and exclusion criteria. When 
the same selection criteria were applied to our patients the median NIHSS varied from 11.5 to 
16.  When applying the clinical selection criteria of MR CLEAN, EXTEND-IA and ESCAPE 
to our patients, a larger proportion had an M2 occlusion. The lower median NIHSS in our less 
selected population raises the possibility of additional differences in patient selection 
processes in published trials that are not evident from trial protocol eligibility alone. The 
unavailability of trial screening log data for the majority of studies published to date limits 
our ability to determine whether additional, non-protocol exclusion criteria were applied. 
Imaging selection criteria varied among the different studies. Non-invasive imaging of the 
intracranial circulation, mostly using CTA, was a minimum requirement in all studies. MR 
CLEAN and THRACE did not specify any additional imaging in patient selection, while all 
other studies used NCCT criteria to exclude patients with large infarct core. The use of CTP 
varied: EXTEND-IA used CTP as the major tissue imaging selection method, while its use in 
SWIFT PRIME, REVASCAT and ESCAPE was variable. It should be noted that CTP was 
also obtained in a large proportion (66%) of MR CLEAN patients, but was not deployed to 
influence patient selection or treatment decisions.  
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About half of our patients were ineligible due to absence of a major vessel occlusion, which 
is similar to the finding in EXTEND-IA. The number of patients excluded based on 
additional parenchymal tissue selection criteria in our sample, however, was significantly 
larger than the 25% reported by the EXTEND IA investigators3, different trial protocols 
excluding between 36 and 64% of patients with ICA or M1 occlusion. This may be a 
consequence of the later presentation times in our population, with onset to IV rtPA treatment 
times of around 180 minutes in our population compared with 85-120 minutes in the trial 
populations. It is clear that different tissue based selection criteria result in large differences 
in the population selected, with SWIFT-Prime criteria excluding many more patients than 
EXTEND-IA criteria. Individual workflow variations make definitive estimates of the impact 
of different imaging criteria difficult: for example, if NCCT ASPECT score is applied before 
knowing a CTA result, a different group is excluded compared to applying an ASPECT score 
to the group with eligible LAO on CTA.  
Our study has limitations. We cannot provide a population-based estimate of the proportion 
eligible, but this was not our goal: rather, we were interested to assess the comparability of 
the different imaging selection strategies. Our study populations were not highly selected, 
predominantly including observational data from patients within 6h of symptom onset and 
applying no exclusions except fitness for follow-up and absence of contraindications to IV 
contrast administration. The ATTEST trial population (comprising 38% of those included 
here) required additional eligibility for IV thrombolysis. While our populations closely 
resembled those reported in the IAT trials, we cannot exclude the possible influence of 
selection biases in our original study populations influencing the findings.  The MR CLEAN 
trial elected to use wide clinical inclusion criteria, and no formal tissue imaging criteria, and 
consequently the majority of our patients would have been eligible for this protocol: the 
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characteristics of our eligible patients correspond closely to the MR CLEAN IAT group, with 
the exception of longer onset to IV rtPA initiation.  
Clinical trial inclusion and exclusion criteria are generally designed to optimise trial 
efficiency, selecting a responder population in order to maximise the treatment effect size and 
thus minimise the sample size. Recognising that this inevitably differs from clinical practice, 
where less restrictive criteria are likely to be employed, we explored a simplified set of 
selection criteria using only presence of LAO and small core (operationalised as 
ASPECTS>6), but even in this setting only 16% of patients would be eligible before applying 
any clinical or tissue selection criteria.  Our data do not allow any conclusions about the 
preferred imaging strategy that would provide the best cost-benefit balance, which will 
require health economic analyses taking into account key infrastructure available in each 
region. Such economic analyses should take into consideration the wide variation in 
requirements for patient transfer and imaging that are implied by our findings. 
  
10 
 
Conclusion: 
 In conclusion, it is likely that around 15% of patients presenting within 6h of symptom onset 
and suitable for imaging selection are potentially eligible for IAT, but additional clinical or 
imaging selection criteria exclude a widely varying proportion of these patients.  The 
assumption that a common clinical population would be identified despite different trial 
selection processes does not appear to be supported from our data26, with large differences in 
those excluded by different criteria, and strikingly only 1% of patients meeting all trial 
protocols.  
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Study 
Clinical Criteria Patients 
ineligibl
e for IV 
rtPA 
CTA criteria Tissue Selection Criteria 
Age Pre-
stroke 
functio
n 
Max Time 
from 
onset to 
endovasc
ular 
therapy 
NIHS
S 
Extra-
cranial  
ICA 
occlusion 
Occluded arteries Baseline 
NCCT 
Perfusion 
Criteria 
Collaterals  
MRCLEAN1 ≥18 any 6 hours ≥2  No Included ICA, M1, M2, A1, 
A2 
Not used for 
selection 
Not used for 
selection 
Not used for 
selection 
ESCAPE2 ≥18 Barthel 
index>
90 
12 hours 5> Included Included, 
except for 
dissection 
ICA,M1, M1 
Equivalent (two or 
more M2 
occlusions) 
ASPECT 
score> 5  
CBV ASPECT 
score used with 
different cut off 
depending on 
coverage  
Collaterals seen in 
more than 50% of 
MCA region by 
multiphase CTA 
EXTEND-
IA3 
≥18 mRS<2 6 hours any No  Not 
included 
ICA,, M1 or M2 Hypodensity 
more than one 
Mismatch 
ratio>1.2 
Not used for 
selection 
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third of MCA 
territory  
Absolute 
mismatch 
volume>10 
Core volume 
<50 ml 
 
REVASCAT
5 
18-
85 
mRS≤1 8 hours ≥6 Included Included ICA or M1 ASPECT>6 
for patients 
>80 years 
ASPECT>9 
for patients 
aged 81-85 
CBV ASPECT 
used in patients 
treated more 
than 4.5 hours 
from symptom 
onset 
Not used for 
selection 
SWIFTPRI
ME4 
18-
80 
mRS≤1 6 hours ≥8-
<30 
No Not 
included 
ICA or M1 ASPECT>6 Used for some 
patients only 
Core volume < 
50 ml 
Not used for 
selection 
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Total infarct > 
100 ml 
Penumbra 
volume > 15 ml 
Mismatch 
ratio≥1.8 
THRACE6 18-
80 
any 4 hours ≥10-
≤25 
No Not 
included 
ICA, M1, upper 
third of basilar 
Not used for 
selection 
Not used for 
selection 
Not used for 
selection 
THERAPY7 18-
85 
mRS=0 Within 
local 
thromboly
sis 
window 
≥8 or 
aphasi
c 
No Not 
included 
Large artery 
occlusion in 
anterior circulation 
Hypodensity 
more than 1/3 
of the MCA 
territory 
Clot more than 
8mm 
Not used for 
selection 
Not used for 
selection 
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Table1: Clinical and Imaging inclusion criteria for 7 endovascular treatment trials. ; MRI based imaging criteria not shown.(NIHSS=National 
Institute of Health Stroke Scale; ICA=Internal Carotid Artery; NCCT=Non Contrast CT; mRS= Modified Rankin Scale; MCA= Middle Cerebral 
Artery; ASPECT=Alberta Stroke Programme Early CT , CBV=Cerebral Blood volume) 
 
 
 Figure 1. The number of patients meeting entry criteria for each of the studies.
 Figure 2. Numbers of patients eligible for different study combinations. MR: MRCLEAN;
TH: Thrace; EX: Extend-IA; ES: ESCAPE RE: REVASCAT; SP: SWIFT-PRIME; TY:
Therapy.
 Figure 3. Number eligible to all studies after applying different clinical and imaging
selection criteria. The top panel shows sequential exclusion of patients based on clinical
criteria, while the bottom panel shows sequential exclusion of patients based on imaging
criteria. Of the eight patients meeting CTP target criteria, only three had a visible clot more
than 8mm, one of the eligibility criteria of THERAPY trial.
 Figure 4. Number of patients with selected for IAT in a hypothetical clinical setting.
